Van Immerseel F, Methner U, Rychlik I, Nagy B, Velge P, Martin G, Foster N, Ducatelle R, Barrow P A
Department of Pathology, Bacteriology and Avian Diseases, Faculty of Veterinary Medicine, Ghent University, Belgium.
Epidemiol Infect. 2005 Dec;133(6):959-78. doi: 10.1017/S0950268805004711.
A recent European Union Directive required member states to put monitoring and control programmes in place, of which vaccination is a central component. Live Salmonella vaccines generally confer better protection than killed vaccines, because the former stimulate both cell-mediated and humoral immunity. Administering Salmonella bacteria orally to newly hatched chickens results in extensive gut colonization and a strong adaptive immune stimulus but broiler chickens are immunologically immature. However, colonization exerts a variety of rapid (within 24 h) protective effects. These include specific colonization-inhibition (competitive exclusion) in which the protective bacteria exert a profound resistance to establishment and colonization by other related bacteria. This is thought to be primarily a metabolic attribute of the vaccinating bacteria but may also involve competition for attachment sites. The presence of large numbers of bacteria originating from a live Salmonella vaccine in the intestine can also induce infiltration of polymorphonuclear cells into the intestinal wall, which confers resistance to invasion and systemic spread by virulent Salmonella strains. This opens new perspectives for vaccine usage in broilers, layers and breeding poultry but also in other animals which show increased susceptibility to infection because of their young age or for other reasons, such as oral chemoprophylaxis or chemotherapy, where the lack of established normal gut flora is an issue. We recommend that all live vaccines considered for oral administration should be tested for their ability to induce the two protective effects described above. Further developments in live Salmonella vaccines are, however, currently hindered by fears associated with the use and release of live vaccines which may be genetically modified.
欧盟最近一项指令要求成员国实施监测和控制计划,其中疫苗接种是核心组成部分。活沙门氏菌疫苗通常比灭活疫苗提供更好的保护,因为前者能刺激细胞介导免疫和体液免疫。给新孵化的雏鸡口服沙门氏菌会导致肠道大量定植并产生强烈的适应性免疫刺激,但肉鸡在免疫上尚未成熟。然而,定植会产生多种快速(24小时内)保护作用。这些作用包括特异性定植抑制(竞争排除),即保护性细菌对其他相关细菌的定植和建立具有很强的抵抗力。这被认为主要是接种细菌的一种代谢特性,但也可能涉及对附着位点的竞争。肠道中存在大量源自活沙门氏菌疫苗的细菌还可诱导多形核细胞浸润肠壁,从而对有毒力的沙门氏菌菌株的侵袭和全身扩散产生抵抗力。这为在肉鸡、蛋鸡和种禽中使用疫苗开辟了新的前景,对于因年幼或其他原因(如口服化学预防或化疗)而对感染易感性增加的其他动物也如此,在这些情况下,缺乏已建立的正常肠道菌群是一个问题。我们建议,所有考虑口服的活疫苗都应测试其诱导上述两种保护作用的能力。然而,目前活沙门氏菌疫苗的进一步研发受到与使用和释放可能经过基因改造的活疫苗相关的担忧的阻碍。